Contact Us: 01282 426380
KM Financial Solutions | Pfizer in talks to merge off-patent drugs business with Mylan
47963
post-template-default,single,single-post,postid-47963,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

Pfizer in talks to merge off-patent drugs business with Mylan

26 Jul Pfizer in talks to merge off-patent drugs business with Mylan

Posted at 12:45h in News by
0 Likes
Pfizer Inc is in talks to merge
its off-patent drugs business with Mylan NV in a stock
deal, the Wall Street Journal reported on Saturday, citing
people familiar with the matter.

No Comments

Sorry, the comment form is closed at this time.